Overview
- Sanofi posted strong Q2 sales growth of 17.8% at constant exchange rates and raised full‑year 2026 revenue guidance to about +10% while reporting a BNPA des activités of €2.09.
- Sanofi disclosed pipeline moves that combine two positive phase‑3 readouts with the decision not to pursue a global regulatory submission for amlitelimab and the termination of itepekimab and balinatunfib programs.
- SPIE delivered H1 revenue of €5.16bn, a rebound in organic growth and an improved EBITA margin of 6.2%, and it underpinned expansion with five bolt‑on deals, a May €600m sustainability‑linked bond and an April Fitch investment‑grade rating.
- Lectra showed Q2 improvement driven by recurring revenue with ARR at €102.6m and stronger EBITDA margin, and the company reiterated its 2026–2028 roadmap that targets steady SaaS ARR growth and margin gains.
- Regional Crédit Agricole units reported sustained commercial momentum, higher net banking income and strong solvency metrics with CET1 ratios above 23% for Ile‑de‑France and a global capital ratio near 27.5% for Morbihan, signaling continued lending support for households and SMEs.